WuXi Biologics Out-licenses mAb Panel to Exelixis for Development

WuXi Biologics of Shanghai out-licensed a panel of mAbs to Exelixis aimed at a pre-clinically validated target. Exelixis, a San Francisco area biotech, will use its technology to develop antibody-drug conjugate, bispecific and certain other novel tumor-targeting biologics applications, based on the mAb panel. Exelixis will make a "modest" upfront payment to WuXi Bio for the license and also be responsible for milestone payments and royalties on any products developed from the WuXi Bio research. More details.... Stock Symbol: (HK: 2269) Share this with colleagues: // //